60 MG HEPCDAC Tablet

60 MG HEPCDAC Tablet is the one indicated for use with sofosbuvir for the treatment of patients with chronic HCV genotype 3 infection in adults. Sustained virologic response (SVR) rates are reduced in HCV genotype 3-infected patients with cirrhosis receiving 60 MG HEPCDAC Tablet in combination with sofosbuvir for 12 weeks.